drugset / Trial / NCT02601287

A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients

NCT02601287 ↗

Phase 4 Completed 168 enrolled Allergan
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a safety and efficacy study of BOTOX® (Botulinum Toxin Type A) in the Treatment of Adult Korean Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity or Overactive Bladder.

Timeline

Start
2015-11
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 100 iu Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 200 iu Intramuscular

Indications